Single-cell RNA Sequencing Resolves the Regulatory Role of HBV on the Hepatocellular Carcinoma Immune Microenvironment

Inclusion Criteria: * Patients with primary liver cancer (hepatocellular carcinoma (HCC)), with evidence of histological or cytological diagnosis, or with HCC meeting conventional clinical diagnostic criteria. * Both sexes, aged 18-80 years old * The results of HBVDNA test were in line with the inclusion criteria * The patient had at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST V1.1) * Agreed to comply with the study protocol for treatment and follow-up, agreed to provide clinicopathological and follow-up data required by the study, and agreed to use the study data for subsequent research and product development Exclusion Criteria: * Other malignant tumors; * Patients with severe organic diseases do not meet the requirements of infectious liver cancer in this study; * Suffering from mental illness cannot guarantee the compliance of this study; * Previous recipients of any cell or organ transplantation; * Received local regional liver therapy (including various ablations, percutaneous ethanol or acetic acid injections, high-intensity focused ultrasound, transarterial embolization, chemotherapy, or chemoembolization plus embolization) within 14 days prior to study treatment initiation.